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David Biedermann 2, Brian Blagg 3, Anuj Khandelwal 3 and Steven B. Marston 1*
1NHLI, Imperial College London, London, United Kingdom, 2 Laboratory of Biotransformation, Institute of Microbiology of the
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The inherited cardiomyopathies, hypertrophic cardiomyopathy (HCM) and dilated
cardiomyopathy (DCM) are relatively common, potentially life-threatening and currently
untreatable. Mutations are often in the contractile proteins of cardiac muscle and cause
abnormal Ca2+ regulation via troponin. HCM is usually linked to higher myofilament
Ca2+-sensitivity whilst in both HCM and DCM mutant tissue there is often an uncoupling
of the relationship between troponin I (TnI) phosphorylation by PKA and modulation
of myofilament Ca2+-sensitivity, essential for normal responses to adrenaline. The
adrenergic response is blunted, and this may predispose the heart to failure under stress.
At present there are no compounds or interventions that can prevent or treat sarcomere
cardiomyopathies. There is a need for novel therapies that act at a more fundamental level
to affect the disease process. We demonstrated that epigallocatechin-3 gallate (EGCG)
was found to be capable of restoring the coupled relationship between Ca2+-sensitivity
and TnI phosphorylation in mutant thin filaments to normal in vitro, independent of the
mutation (15 mutations tested). We have labeled this property “re-coupling.” The action
of EGCG in vitro to reverse the abnormality caused by myopathic mutations would
appear to be an ideal pharmaceutical profile for treatment of inherited HCM and DCM
but EGCG is known to be promiscuous in vivo and is thus unsuitable as a therapeutic
drug. We therefore investigated whether other structurally related compounds can
re-couple myofilaments without these off-target effects. We used the quantitative in vitro
motility assay to screen 40 compounds, related to C-terminal Hsp90 inhibitors, and
found 23 that can re-couple mutant myofilaments. There is no correlation between
re-couplers and Hsp90 inhibitors. The Ca2+-sensitivity shift due to TnI phosphorylation
was restored to 2.2 ± 0.01-fold (n = 19) compared to 2.0 ± 0.24-fold (n = 7) in
wild-type thin filaments. Many of these compounds were either pure re-couplers or
pure desensitizers, indicating these properties are independent; moreover, re-coupling
ability could be lost with small changes of compound structure, indicating the possibility
of specificity. Small molecules that can re-couple may have therapeutic potential.
Sheehan et al. Cardiomyopathy Intervention by Small Molecules
HIGHLIGHTS
- Inherited cardiomyopathies are common diseases that are currently untreatable at a
fundamental level and therefore finding a small molecule treatment is highly desirable.
- We have identified a molecular level dysfunction common to nearly all mutations:
uncoupling of the relationship between troponin I phosphorylation and modulation of
myofilament Ca2+-sensitivity, essential for normal responses to adrenaline.
- We have identified a new class of drugs that are capable of both reducing
Ca2+-sensitivity and/or recouping the relationship between troponin I phosphorylation
and Ca2+-sensitivity.
- The re-coupling phenomenon can be explained on the basis of a single mechanism
that is testable.
- Measurements with a wide range of small molecules of varying structures can indicate
the critical molecular features required for recoupling and allows the prediction of other
potential re-couplers.
Keywords: cardiomyopathy, sarcomeric protein mutations, troponin I phosphorylation, PKA, Ca2+ regulation,
small molecule pharmacology, EGCG, silybin
INTRODUCTION
The contractile apparatus of cardiac muscle is controlled by the
sarcoplasmic Ca2+-level acting upon the Ca2+ sensor, troponin.
Troponin, together with tropomyosin and actin constitutes the
thin filaments of muscle. In unstimulated muscle contraction is
inhibited by the C-terminus of the troponin I subunit binding
to actin-tropomyosin and blocking the interaction with myosin
crossbridges. Upon stimulation intracellular Ca2+ rises and Ca2+
binds to the troponin C subunit (TnC), the C-terminus of TnI is
released from its site on actin and crossbridge cycling can proceed
(Gordon et al., 2000; MacLeod et al., 2010). Thus changes in Ca2+
level switch contraction on and off. However contractility in
heart muscle is additionally modulated through the β-receptors.
Activation of β1- receptors by adrenaline initiates formation
of cAMP and activation of Protein Kinase A (PKA) leading
to increased rate and magnitude of contraction. Lusitropy, an
increased rate of relaxation allowing for shorter twitch duration,
is a key component of adrenergic activation and involves TnI.
Phosphorylation of ser22 and 23 of TnI by PKA leads to a 2-fold
decrease in Ca2+-sensitivity and a corresponding increase in the
rate of Ca2+ release from TnC and is essential for the lusitropic
response (Robertson et al., 1982; Kentish et al., 2001; Layland
et al., 2005).
Whilst the structural mechanism of the troponin Ca2+
switch is well-documented (Takeda et al., 2003), the structural
basis of lusitropy is poorly understood since both the
phosphorylated N-terminal peptide and the regulatory “switch
peptide” of TnI are intrinsically disordered, however recent
studies using molecular dynamics simulations have begun to
explain this phenomenon (Papadaki and Marston, 2016). The
study of this phosphorylation dependent regulation has been
recently stimulated by the discovery that a primary effect
of many mutations in thin filament proteins associated with
cardiomyopathy is the uncoupling of this relationship (Bayliss
et al., 2012; Memo et al., 2013; Messer and Marston, 2014).
Dilated cardiomyopathy (DCM) and hypertrophic
cardiomyopathy (HCM) are often due to single mutations
in a protein of the sarcomere and have been extensively
studied in vitro. It is estimated that 1/250 of the population
show symptoms of DCM, and that 40% of cases are inherited
(Hershberger et al., 2013). Truncating mutations in the titin
(TTN) gene are the most common but a substantial fraction
(12%) of mutations are in the proteins of the thin filament.
HCM is estimated to be present in 1/500 of the population; it is
overwhelmingly an inherited disease and the majority of known
disease causing mutations are in the contractile proteins of the
heart muscle sarcomere (Walsh et al., 2017). It is a leading cause
of sudden cardiac death in young adults, particularly athletes
and if not controlled can lead to heart failure (Lopes and Elliott,
2014).
In HCM, mutations generally cause an increase of about 1.5-
to 2-fold in myofilament Ca2+-sensitivity that is considered to
be sufficient to induce the symptoms of HCM. The effect of
DCM mutations in contractile proteins on Ca2+-sensitivity is
variable with a trend toward deceased Ca2+-sensitivity (Marston,
2016). Importantly for this study it has been shown that HCM
and DCM-related mutations in contractile proteins usually
abolish the coupled relationship between Ca2+-sensitivity and
TnI phosphorylation by PKA: we have called this phenomenon
“uncoupling” (Memo et al., 2013; Messer and Marston, 2014;
Messer et al., 2016). A blunting of the response to β-adrenergic
activation is commonly observed in animal models with HCM or
DCM mutations and it has been demonstrated in a DCM mouse
model that this blunting is sufficient to induce heart failure under
chronic stress (Messer andMarston, 2014;Wilkinson et al., 2015).
At present there are no compounds or interventions that
can prevent or treat sarcomeric cardiomyopathies and current
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treatments available are directed at alleviating the symptoms.
There is a need for novel therapies that act at a more fundamental
level to affect the disease process (Tardiff et al., 2015). In our
studies of the uncoupling effects of mutations we demonstrated
that epigallocatechin-3 gallate (EGCG), originally studied as a
Ca2+ desensitizer (Tadano et al., 2010; Friedrich et al., 2016), was
also found to be capable of restoring the coupled relationship
between Ca2+-sensitivity and TnI phosphorylation in mutant
thin filaments to normal in vitro, a property we refer to as “re-
coupling” (Papadaki et al., 2015; Messer et al., 2016, 2017). The
action of EGCG in vitro to reverse the abnormality caused by
myopathic mutations would appear to be an ideal pharmaceutical
profile for treatment of inherited HCM and DCM. However,
EGCG is known to have pleiotropic pharmaceutical properties in
intact tissue, including inotropic activity, making it an unsuitable
therapeutic drug (Singh et al., 2011; Feng et al., 2012; Baell and
Walters, 2014; Ingólfsson et al., 2014). Moreover, this compound
is not easily available in its pure state and it is not sufficiently
stable under oxidative and hydrolytic conditions. Therefore, it
is important to investigate whether other structurally related
compounds can also re-couple myofilaments without these off-
target effects.
EGCG and its analogs have been widely studied as Hsp90
inhibitors, so we began our investigations using analogs of EGCG
and of Silybin, a natural product with structural similarity,
originally studied as Hsp90 inhibitors (Hao et al., 2010; Zhao
et al., 2011; Khandelwal et al., 2013). We used the quantitative
in vitromotility assay to screen 40 compounds and found 23 that
can re-couple mutant myofilaments. Many of these compounds
were either pure re-couplers or pure desensitizers, unlike EGCG
that has both properties. Moreover, re-coupling ability could
be lost with minor modifications in the compound structure,
indicating the possibility of specificity. Consideration of the
molecular structures of re-coupling molecules (structure-activity
relationships, SAR), compared with similar inactive molecules
can provide considerable insight into the mechanism of re-
coupling and may lead to the discovery of more potent re-
coupling (lead) compounds with therapeutic potential.
METHODS
Sources of Contractile Proteins
Troponin was isolated from donor heart tissue, supplied
by Sydney Tissue Bank, University of Sydney, Australia. St
Vincent’s Hospital Sydney and Brompton, Harefield and NHLI
Research Ethics Committees provided ethical approval for the
collection of and experimentation with tissue samples (Lal et al.,
2015). Donors had no previous history of heart disease and
unremarkable ECG.
An anti-cardiac TnI monoclonal antibody affinity column was
used to isolate troponin from 100mg of donor heart tissue as
previously described (Messer et al., 2007). This troponin has
an intrinsically high level of TnI phosphorylation (1.6–2.2mol
Pi/mol). To reduce the phosphorylation level (<0.3mol Pi/mol)
troponin was treated with shrimp alkaline phosphatase (Memo
et al., 2013). The level of TnI phosphorylation was measured by
phosphate affinity SDS–PAGE as previously described (Messer
et al., 2009).
Recombinant human sequence tropomyosin was a gift from
Kristen Nowak and Elyshia MacNamara, University, Western
Australia. Wild-type α-tropomyosin (Tpm1.1) and mutant
E180G tropomyosin were expressed in a baculovirus/Sf9 system
(Akkari et al., 2002; Marston et al., 2013). Skeletal muscle F-actin
and myosin were isolated from rabbit fast-twitch skeletal muscle
as previously described (Messer et al., 2007). TnC G159Dmutant
troponin was extracted from amutant human heart sample (Dyer
et al., 2009), E99K mutant cardiac actin was extracted from the
E99K transgenic mouse heart (Song et al., 2013).
EGCG- and Silybin-Related Compounds
The analogs of EGCG labeled 1–28 were prepared as described
by Khandelwal and Blagg (Khandelwal et al., 2013). Table 1
identifies the compounds in that paper and the molecular
structures are shown in Figure S1. Silybin diastereomereomers
and silmarin-derived pure flavonolignanswere isolated as
described by Kren et al. (Gažák et al., 2011; Krenek et al., 2014;
Novotná et al., 2014) (for structures see Figure S1). All other
compounds were purchased from Sigma-Aldrich. Dose was
100µM from a 10mM stock in DMSO unless otherwise stated.
Quantitative in Vitro Motility Assay (IVMA)
Thin filaments were reconstituted with 10 nM rabbit skeletal or
mouse cardiac muscle α-actin (labeled with TRITC phalloidin),
tropomyosin (40–60 nM), and troponin (60 nM) to study Ca2+-
regulation of filamentmotility by the quantitative in vitromotility
assay (IVMA) (Fraser and Marston, 1995; Messer et al., 2007).
Thin filament movement over a bed of immobilized rabbit fast
skeletal muscle heavy meromyosin (100µg/ml) was compared in
paired motility cells, in which troponin varied by a single factor
(mutation, phosphorylation state, or treatment with drug). The
temperature was set to 29◦C. Filament movement was recorded
and analyzed as previously described (Marston et al., 1996),
yielding two parameters, the fraction of filaments moving and the
speed of moving filaments. Only the fraction of filaments motile
is used in this study.
The fraction motile was measured over a range of Ca2+
concentrations to generate Ca2+-activation curves. The data were
fitted to the 4-variable Hill equation to yield a value for EC50
and nH. Most assays of the effect of compounds are single
measurements. When appropriate EC50 values from replicate
experiments were analyzed by paired t-test since the distribution
of EC50 has been shown to be normal. Error bars and n values are
given in tables and figures.
For drug screening, motility was measured with paired
phosphorylated and unphosphorylated tropomyosin E180G
mutant-containing thin filaments at a fixed 0.037µMCa2+. Most
assays were single measurements.
RESULTS
EGCG Can Re-couple Every Uncoupling
Mutation Tested
Wemeasured the Ca2+ activation of contractility using an in vitro
motility assay that measures the movement of reconstituted thin
filaments over a bed of immobilized myosin heads. A series of
measurements, some of which have been previously published
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TABLE 1 | Ability of small molecules to re-couple troponin in thin myofilaments


















12.0 47µM E54K, E99K
1 1.0
2 (23h) 27.0 30µM 22µM
3 (27a) 8.0 14µM
4 (23p) 27.0 34µM >100µM
5 2.0
6 1.0
7 (27c) −11.0 67µM E54K, E99K 32µM
8 (27p) No Effect 38µM
9 (23q) 20.0 35µM >100µM
10 No Effect
11 (10c) 7.0 E54K >100µM
12 (23f) −1.0 No Effect 63µM
13 No Effect
14 17.0 36µM
15 (10j) 13.0 19µM
16 (27h) 6.0 31µM 8µM
17 (23b) 3.5 58µM
19 (27g) 24.0 21µM
20 2.0
21 (11d) 25.0 14µM
22 7.0
23 (23a) 9.0 98µM
24 8.0 24.5µM
26 (7a) 26.0 E54K
27 (31d) 4.0 55µM











Silybin A 5 G159D
Silybin B 55 39µM G159D
Dehydrosilybin A 3 G159D





























Test system as shown in Figure 2. Compounds 1–28 were synthesized by Blagg and
Khandelwal; their corresponding identification numbers in the original paper are given
in brackets and the structures are shown in the supplement (Khandelwal et al., 2013).
Difference between motility (%) in phosphorylated and unphosphorylated forms of thin
filaments (and EC50, when measured) with TPM1 E180G HCM mutation are shown.
Other mutations also used in this test are E54K, TPM1 E54K DCMmutation; E99K, ACTC
E99KHCMmutation andG159D, TNNC1G159DDCMmutation. Compounds highlighted
in green are effective re-couplers. Compounds highlighted in red indicate reverse re-
coupling where Ca2+-sensitivity of the phosphorylated Tn I is greater than that of the
dephosphorylated Tn I. In orange is the reverse re-coupler #7. For comparison the last
column shows the effectiveness of these compounds in an assay for Hsp90 inhibition;
effective Hsp90 inhibitors are highlighted in green and EC50 is given when measured
(Khandelwal et al., 2013).
(Papadaki et al., 2015; Messer et al., 2016, 2017), are summarized
in Figure 1. These determinations of EC50 show that in every
case where a mutation causes uncoupling of Ca2+-sensitivity
from TnI phosphorylation, EGCG can restore the coupling (re-
couple). Thus, the effect of EGCG is independent of the mutation
that induced uncoupling; in addition, both in man and cat, HCM
cases were found where no mutation in sarcomeric genes was
detected yet the thin filaments were uncoupled and they could
also be re-coupled by EGCG (Bayliss et al., 2012; Messer et al.,
2016).
Rapid Screening for Re-coupling
Functionality
For the rapid screening of compounds, we devised a single
Ca2+ concentration assay. This is illustrated in Figures 2A,B
for quercetin. The test system contains skeletal muscle actin,
human sequence recombinant tropomyosin 1.1 containing the
E180G HCM-associated mutation and human cardiac troponin
from donor hearts in the phosphorylated and unphosphorylated
form. At 0.037µM Ca2+ the filaments are about 40% motile
irrespective of phosphorylation level whilst when quercetin
is added the phosphorylated Ca2+ activity curve shifts to
the right and % motility at 0.037µM Ca2+ drops, whilst
the unphosphorylated level is unchanged. We have set a
difference between phosphorylated and unphosphorylated>10%
as indicating re-coupling activity. This assay method can
also be used to construct a dose-response curve as shown.
Table 1 and Figures 2C,D show the results from screening
40 compounds in this assay. We investigated compounds in
4 categories.
1 Variants of EGCG lacking the pyrogallol ring (Khandelwal
et al., 2013).
2 Variants of EGCG lacking the galloyl moiety (Tadano et al.,
2010).
Frontiers in Physiology | www.frontiersin.org 4 March 2018 | Volume 9 | Article 243
Sheehan et al. Cardiomyopathy Intervention by Small Molecules
FIGURE 1 | EGCG recoupling of troponin. Ratio of EC50 for phosphorylated and unphosphorylated thin filaments is plotted for thin filaments that are uncoupled.
EC50 was determined from Ca
2+-concentration plots; see Figures 2A, 4A,C,D for examples. Raw EC50 data is given in Table S1. EC50 was measured by in vitro
motility assay in the presence (red bars) and absence (blue bars) of 100µM EGCG. Mutant troponin or tropomyosin was from tissue (mouse, cat or human) with
mutations in TnC (TNNC1), TnI (TNNI3), TnT (TNNT2), Actin (ACTC), tropomyosin (TPM1), myosin binding protein C (MYBPC3), and from cat heart with HCM and
Human heart material from myectomy operations to relieve HCM; in the latter two cases samples were genotyped but no causative mutation was found. EGCG
restored coupling to all the uncoupled systems. Includes data from (Papadaki et al., 2015; Messer et al., 2016, 2017).
3 Silybin, its derivatives and stereoisomers, since this has also
been proposed as an Hsp90 C-terminal inhibitor (Gažák et al.,
2011; Zhao et al., 2011).
4 Unrelated Hsp90 inhibitors and Ca2+-desensitizers (Hall
et al., 2014).
For structures see Figure S1.
Re-couplers were clearly distinguishable from inactive
compounds: 23/40 compounds were classed as re-couplers.
A series of dose-response curves (Figure S2) indicate the
magnitude of recoupling is approximately the same for all
compounds measured together and the EC50 for EGCG and
Silybin derivatives are similar, being in the range 30–60µM
(see Table 1). It should be noted that Ca2+-sensitisers and
the myosin activator Omecamtiv Mercarbil do not re-couple
(Figure 2).
Interestingly, one compound, #7, had a reverse effect—the
phosphorylated troponin was more Ca2+-sensitive than the
unphosphorylated troponin condition. The standard assay used
E180G mutant tropomyosin as the uncoupling mutation but,
as with EGCG, recoupling was independent of the mutation
type when tested with uncoupled thin filaments containing
TPM1 E54K, ACTC E99K, or TNNC1 G159D mutations
as indicated in Table 1. It is interesting to note that when
Ca2+ sensitivities of the phosphorylated and unphosphorylated
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FIGURE 2 | Single [Ca2+] screen for re-coupling compounds. (A) Ca2+-activation curves for phosphorylated and unphosphorylated thin filaments containing E180G
tropomyosin in the presence and absence of 25µM Quercetin, a typical pure recoupler. Solid lines, phosphorylated state; dotted lines, unphosphorylated state. Purple
lines and points, E180G thin filaments; green lines and points, E180G thin filaments + Quercetin (B) Dose -response curve for quercetin recoupling activity measured
at a constant concentration of 0.037µM Ca2+. INSET, kinetic analysis of dose response curve; difference between phosphorylated and unphosphorylated states is
plotted against quercetin concentration. The Hill equation is fitted to the data, EC50 = 8µM. (C,D) The effect of 100µM drug treatment on the difference between %
of motility of phosphorylated and unphosphorylated tropomyosin E180G mutant-containing thin filaments at 0.037µM Ca2+. (C) EGCG-related molecules (for
structures 1–28 see Figure S1 and Table 1). (D) Silybin, related compounds and other HsP90 inhibitors and Ca2+ desensitizers. The threshold for positive re-coupling
was set at a 10% difference (dotted line).
troponin of re-coupled systems were measured, the shift in
Ca2+-sensitivity was restored to a value close to the shift in
Ca2+-sensitivity previously observed in PKA-phosphorylated
native thin filaments. (see Figure 3 and Table S1). Following
this preliminary screening, selected compounds were further
investigated.
There Is No Correlation Between
Re-couplers and Hsp90 Inhibitors
Although many of the compounds investigated were selected
from a study on Hsp90 inhibitors, there does not seem to be
any correlation between their efficacy as re-couplers and Hsp90
inhibition. Thus, for the EGCG analogs tested (1–28) there
were four compounds that were both Hsp90 inhibitors and re-
couplers, four that were re-couplers only, four that were Hsp90
inhibitors only and seven that were inactive in both assays
(Table 1).
The Ca2+-Desensitizer and Re-Coupling
Activities May Be Separated
Although the lead compound, EGCG, was both a desensitizer and
a re-coupler, we found that most of the compounds we studied
did not have both properties. Some were desensitizers alone but
the majority were re-couplers that did not influence myofilament
Ca2+-sensitivity in WTmuscle. Thus, the two activities of EGCG
are not intrinsically linked.
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FIGURE 3 | Phosphorylation-dependent change in thin filament
Ca2+-sensitivity. Frequency histogram showing the distribution of the ratio of
Ca2+-sensitivity in the phosphorylated and unphosphorylated state. The
X-axes shows the ratio of EC50 unphosphorylated/phosphorylated and the
corresponding shift in pCa50. Collected data from different mutations
(Figure 1) and different recoupling compounds (Figure 2) is plotted. Red bars
show distribution of shift in Ca2+ sensitivity on phosphorylation for mutant thin
filament samples (n = 22 measurements by in vitro motility assay) showing no
difference in Ca2+ sensitivity (uncoupling). Dark green bars show distribution
of Ca2+ sensitivity shift from the same samples following the addition of small
molecule recouplers. For comparison, the Ca2+-sensitivity shift on
phosphorylation of native thin filaments and skinned muscle using a range of
measurement systems is plotted (pale blue bars; n = 9, data from Marston,
2016, Table 5).
Epicatechin gallate (ECG) is an example of a compound that
is a pure desensitizer as illustrated in Figures 4A,B. When added
to thin filaments that contain the uncoupling mutation E180G
in tropomyosin, ECG equally reduces the Ca2+-sensitivity of
both phosphorylated and unphosphorylated thin filaments so
the system remains uncoupled. Silybin A also acts as a pure
desensitizer (Figure 4C, Figure S2B).
Many of the compounds investigated were pure re-couplers.
This is best demonstrated by their inability to influence the Ca2+-
sensitivity of native thin filaments in either the phosphorylated
or unphosphorylated state, in contrast to EGCG (Figure 4E). In
mutant-uncoupled thin filaments, the pure recoupling ability is
shown by the decrease in Ca2+-sensitivity of phosphorylated but
not the unphosphorylated mutant thin filament in the presence
of the compound as shown for Silybin B in Figure 4D, Quercetin
in Figure 2A and Dehydrosilybin B in the Figure S3. In the
rapid single Ca2+ concentration assay a large difference between
% motility in the phosphorylated and unphosphorylated states
is found in fully coupled systems. In wild-type thin filaments
the difference is unaffected by the compounds indicating that the
compound does not change wild-type Ca2+-sensitivity, whilst the
value in E180G thin filaments is low, indicating uncoupling, but
is restored by the compounds, indicating re-coupling.
Figure 4F illustrates this behavior for 10 compounds. We did
not identify any compound apart from EGCG that was both a
desensitizer and a re-coupler and 15 out of 40 compounds had
no desensitizing or recoupling effects.
Minimal Effective Structure
Since both EGCG and Silybin are quite large molecules, we
investigated whether re-coupling could be achieved with smaller
molecules. We found that removal of the pyrogallol ester moiety
or the galloyl moiety, but not both, had no effect on re-coupling
activity. Similarly, in Silybin it was possible to remove the lignan
part without altering the compound’s activity; thus, a substituted
chromanone or chromane ring plus a phenolic ring seem to
be sufficient for re-coupling (Figures 5A,B). We also observed
that simpler structures such as the two-ring molecules, e.g.
Resveratrol, Pterostilbene, compound #2 (Figure 5), and even
the single ring calmodulin antagonist W-7 were effective re-
couplers (Figure 2, Table 1). This suggests that it is not the
chromane/chromanone ring system that is essential but rather
the substitutions that define the charge structure in ring A.
Small Differences Change Function
It is remarkable that the re-coupling function can be lost with
small changes in key parts of the structure. For instance the
change of an OH to H in the D ring of EGCG is sufficient
to abolish recoupling whilst preserving desensitization (ECG,
Figure 4A). The stereoisomers of Silybin and Dehydrosilybin,
which have four or two chiral centers, respectively, have quite
different activities. The B isoforms are good re-couplers contrary
to the A isoforms (Figures 2, 4D, Figures S2B, S3).
A group of compounds with substitutions containing the core
rings A, C, and D of EGCG shift function from good recoupling
to no effect and even to reverse re-coupling. The structural
differences are small, for instance compound 19 (re-coupler) and
compound 7 that has a reverse effect differ only by the number
and positions of O-methyl groups in the D ring whilst other
substitutions in the D ring (compounds 8 and 16) render the
compound inactive. In addition, a number of substitutions in the
A ring are compatible with recoupling when combined with an
appropriate substitution in the D ring (compounds 9, 19, and 2)
(Figures 5C,D). Methylation can alter properties of compounds
since the phenolic OH is a weak acid and it is thus available as
H-bond acceptor; OMe is also an H-bond acceptor but rather
weaker and the acidity is lost. The position of free OH on the
phenolic ring is likely to be important; for instance there is a huge
difference in the reactivity of OHs in the ortho(para) and meta
positions.
DISCUSSION
Mutations in contractile proteins can cause familial HCM or
familial DCM. HCM has been linked to a higher myofilament
Ca2+-sensitivity. In addition, we have identified a molecular
level dysfunction common to both HCM and DCM-causing
mutations (Papadaki et al., 2015; Messer et al., 2016). This is
an uncoupling of the relationship between TnI phosphorylation
and modulation of myofilament Ca2+-sensitivity, essential for
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FIGURE 4 | Separation of desensitization and recoupling activities (A,B) Epicatechin gallate (ECG) is a desensitizer but not a recoupler. (A) Ca2+-activation curves for
phosphorylated and unphosphorylated thin filaments containing E180G tropomyosin in the presence and absence of 25µM ECG. Solid lines, phosphorylated; dotted
lines, unphosphorylated. Purple lines and points, E180G thin filaments; green lines and points, E180G thin filaments + ECG. (B) Dose-response curve for ECG activity
measured at a constant Ca2+ concentration of 0.037. (C,D) Silybin A is a pure desensitizer whilst Silybin B is a pure recoupler Ca2+ activation curves are shown for
phosphorylated and unphosphorylated thin filaments containing TnC G159D (DCM mutation) that are uncoupled. (C) In presence and absence of silybin A, (D) in
presence and absence of Silybin B. Solid lines, phosphorylated; dotted lines, unphosphorylated. Purple lines and points, E180G thin filaments; green lines and points,
E180G thin filaments + Silybin A or B. Structures of Silybin A and B are shown below the plots. (E,F) Compounds that recouple but are not Ca2+-desensitizers.
(E) The effect of compounds on Ca2+-sensitivity of wild-type thin filaments. The ratio of EC50 in the presence and absence of tested compounds is plotted for the
phosphorylated (dark green) and unphosphorylated (light green) states. Only EGCG is a significant desensitizer. DHSA/B, Dehydrosilybin A/B. (F) The effect of 100µM
drug treatment on the difference in fraction motile between phosphorylated and unphosphorylated states at 0.037µM Ca2+ in the phosphorylated and
unphosphorylated states (see Figures 2C,D). Red bars, WT troponin; pink bars, WT troponin + compound. Dark green bars, E180G thin filaments, light green bars,
E180G thin filaments + compound. Wild-type difference is unaffected by compound (not a desensitizer), whilst the value in E180G thin filaments is low indicating
uncoupling, but restored by the compound indicating re-coupling.
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FIGURE 5 | Structure-function relationships (A,B) Minimal structures that re-couple. (C,D) Small changes in A and D ring of EGCG determine recoupling activity (C),
Dose-response curves for re-couplers #9 and #19, inactive compound #12 and reverse re-coupler #7. (D) Structures of related re-coupling, inactive, and reverse
recoupling compounds.
normal responses to adrenaline. As a consequence, adrenergic
response is blunted in vivo, which predisposes to heart failure
under stress (Messer and Marston, 2014; Wilkinson et al., 2015).
Thus uncoupling at the contractile protein level contributes to
the symptoms of HCM and DCM and restoration of coupling
is a significant target for therapy (Tardiff et al., 2015). We
have identified compounds that can specifically reverse these
abnormalities in vitro and therefore have potential for treatment
that we call “re-couplers.” The first compound studied was
Epigallocatechin-3-gallate (EGCG) (Tadano et al., 2010). EGCG
is capable of both Ca2+ desensitization and re-coupling in
mutant thin filaments (Papadaki et al., 2015). We have now
identified a further 23 structural analogs that are capable
of restoring coupling in vitro; many of these can re-couple
independent of Ca2+-desensitization.
Mechanism of Coupling, Uncoupling, and
Re-coupling
The normal change in myofilament Ca2+-sensitivity due to TnI
phosphorylation by PKA is reported to be 2.00 fold ± 0.24
(EC50 P/unP, see Marston, 2016). It is remarkable that our
current measurements show the same Ca2+ sensitivity shift
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FIGURE 6 | Allosteric model for modulation of Ca2+ -sensitivity by
phosphorylation, mutations, and small molecule recouplers.
in phosphorylated and unphosphorylated mutant-containing
thin filaments when re-coupled (mean EC50 P/unP 2.2 ± 0.1
(n = 19) (Figure 3). This indicates a complete restoration of
Ca2+ sensitivity modulation by TnI phosphorylation that is
independent of the nature of the re-coupling compound and
independent of the cardiomyopathy-related mutation (Figure 1).
Therefore, it is reasonable to propose that these perturbations
act by changing the equilibrium between a small number of
pre-existing states.
We propose that troponin exists in four functional states:
phosphorylated form with high and low Ca2+-sensitivity and
unphosphorylated form with high and low Ca2+ sensitivity
(Figure 6). This model can account for the effects of TnI
phosphorylation in wild-type and mutant (uncoupled) thin
filaments and also the effects of re-coupling compounds.
In wild-type muscle, phosphorylation results in a transition
from the unphosphorylated, high Ca2+ sensitivity state to
the phosphorylated low Ca2+ sensitivity state (red arrows).
Mutations that produce uncoupling can only undergo
transition from the unphosphorylated high Ca2+ sensitivity
to phosphorylated high Ca2+ sensitivity state and the further
transition to low Ca2+ sensitivity is blocked. Dvornikov
et al. have proposed structural evidence that a normal
phosphorylation-dependent structural transition is blocked
in the TnI R145W HCM mutant troponin (Dvornikov et al.,
2016). It is remarkable that the uncoupling phenomena can be
induced by a wide range of mutations and other perturbations
(Figure 1) and this suggests that the phosphorylated low affinity
state is rather unstable and the high affinity state may be a default
state.
The functions of small molecules can be accounted for by
their preferential binding to, and hence stabilizing of, one
or more troponin states. Thus, a small molecule could re-
couple by preferentially binding to the phosphorylated low
affinity state, which would overcome the blocked transition from
phosphorylated high affinity state to low affinity phosphorylated
state. In such a mechanism the small molecule would have no
effect upon the transitions of wild-type troponin, as observed.
Molecules that desensitize mutant thin filaments without
re-coupling (ECG, Silybin A) could be accounted for if they
bound equally to the phosphorylated and unphosphorylated low
affinity states. The reverse re-coupler, compound #7, could be
incorporated into this scheme if it is preferentially bound to the
unphosphorylated low Ca2+ affinity state. Such predictions could
be tested if ligand binding to wild-type and mutant troponin
in the different states could be measured; in the absence of
such techniques, molecular dynamics simulations of the ligands
bound in phosphorylated and unphosphorylated states would be
a suitable approach (Zamora et al., 2017).
Troponin Structural Correlations
Although structural determinations of ligand binding (EGCG,
W-7) to troponin subunits have been made, most studies
have involved binary complexes (TnI and TnC) and partial
sequences (Robertson et al., 2010; Botten et al., 2013; Hwang
and Sykes, 2015). Recent molecular dynamics simulations have
emphasized the importance of studying the intact troponin
core with TnI, TnC, and TnT present (Papadaki and Marston,
2016; Zamora et al., 2016). Moreover, studies on the docking
of EGCG, Silybin A and Silybin B by molecular dynamics
simulations suggest that these compounds bind and crosslink the
N-terminal peptide of TnI in the vicinity of the phosphorylatable
serines22 and−23 to the N terminal domain of TnC and that
the three compounds have different dynamics. In this position
the re-coupling compound could influence the phosphorylation-
dependent modulation of Ca2+-sensitivity of TnC compatible
with our four state model (Zamora et al., 2017).
It is notable that the phosphorylatable N-terminus and
the “switch peptide” of TnI, critical for Ca2+-regulation, are
intrinsically disordered peptides (Hwang et al., 2014; Papadaki
and Marston, 2016). By analogy with similar disordered peptides
containing regulatory phosphorylation sites it is suggested that
there may be negligible differences in time-averaged structures
between phosphorylated and unphosphorylated states, but rather
phosphorylation induces a change in protein dynamics from an
ordered to a less ordered state (Colson et al., 2012).
More precise structure-function analysis requires further
extensive docking modeling, however, it appears that the
substituted chromane (in EGCG) or chromanone (in Silybin)
are fundamental. The way in which the substitutions define the
structure, charge distribution, hydrogen bonding potential or
acidity of the A ring, apparently involved in its intercalation
between TnI and TnC, is likely to be critical for the compound
effect. In the EGCG analogs it seems that either the B ring
(pyrogallol) or the D ring (galloyl) are sufficient to confer
re-coupling activity, so one ring may be able to assume the
configuration of the other when one of them is absent. In
Silybin and Dehydrosilybin, the lignan part is not fully needed
for function (taxifolin, quercetin) and only the B isomers
are recouplers, whilst the A stereoisomers of Silybin and
Dehydrosilybin are inactive as recouplers. In this case it seems
likely that the A isomers have an unfavorable conformation that
prevents the A and D rings binding in the same way as the B
isoform. It is noteworthy that the B isomer is more active than
the A isomer is several different bio-assays (Kren and Walterová,
2005; Biedermann et al., 2014).
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Physiological Correlates
The main effect of uncoupling of the modulation of Ca2+
sensitivity by TnI phosphorylation is the loss of the lusitropic
response to beta adrenergic stimulation, which is usually
accompanied by blunting of the whole physiological adrenergic
response. This is demonstrated most directly by a lack of
response to dobutamine stimulation observed at the whole
animal, papillary muscle and single cardiomyocyte levels (Song
et al., 2010, 2011; Wilkinson et al., 2015). Tadano showed
that EGCG restored the impaired pump function due to
diastolic dysfunction in a transgenic HCM mouse model
(Tadano et al., 2010). Our preliminary experiments in isolated
cardiomyocytes from ACTC E99K HCM transgenic and non-
transgenic mice (Marston et al., 2018) show that the lusitropic
effect of dobutamine is blunted in ACTC E99K mouse but
could be restored by Resveratrol and Silybin B, whilst the
effect of EGCG is anomalous, reflecting the known off target
effects, especially positive inotropy (Feng et al., 2012). Further
structural and functional investigations of these compounds
could produce a new lead compound to direct our search for
an effective and specific re-coupler with a practical potential in
the treatment of inherited cardiomyopathies at the fundamental
level.
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